Background. Antiretroviral therapy (ART) used as preexposure prophylaxis (PrEP) by human immunodeficiency virus (HIV)-seronegative individuals reduces the risk of acquiring HIV. However, the population-level impact and cost-effectiveness of using PrEP as a public health intervention remains debated.
There is increasing interest in the use of preexposure prophylaxis (PrEP) with antiretroviral medications to prevent the acquisition of human immunodeficiency virus (HIV). The efficacy of PrEP has been demonstrated in 4 randomized controlled trials: the iPrEX trial [1] , the Partners PrEP study [2] , the TDF2 Study [3] , and the Bangkok Tenofovir Study [4] . The iPrEX trial randomly assigned 2499 HIV-seronegative men and transgender women who have sex with men to receive a combination of 2 oral antiretroviral drugs, emtricitabine and tenofovir disoproxil fumarate (FTC-TDF), or placebo once daily. This study reported a 44% reduction in HIV incidence among the FTC-TDF group [1] . The Partners PrEP study randomized 4758 serodiscordant heterosexual couples to TDF, FTC-TDF, or placebo once daily. Baeten and colleagues reported a 75% reduction in HIV incidence among the FTC-TDF group-with medication in use 92.1% of the total followup time [2] . The TDF2 Study randomly assigned 1219 HIV-seronegative sexually active heterosexual men and women to receive either FTC-TDF or a matching placebo once daily. In this study, FTC-TDF, taken orally once daily, decreased the rate of HIV infection by 62% [3] . The Bangkok Tenofovir Study randomized 2413 injecting drug users to receive TDF or placebo once daily, with the TDF arm having a 48.9% reduced risk of HIV infection [4] .
On the basis of these findings, PrEP with FTC-TDF or TDF is being recommended for wider use for the prevention of HIV infection [5, 6] . However, the cost-effectiveness of PrEP in a real-world setting remains undecided. The incremental cost-effectiveness ratio (ICER) for PrEP among high-risk men who have sex with men (MSM) in the United States has ranged between $31 970 per quality-adjusted life year gained (QALYG) (2007 US dollars) [7] and $298 000 per QALYG (2006 US dollars) [8] . Such modeled analyses remain highly sensitive to several real-world variables. These include the level of uptake and adherence among high-risk groups, the risk of resistance and toxicity, behavioral disinhibition, and drug costs. The objective of this study was to weigh the uncertainties surrounding PrEP in a real-world setting and determine in what clinical, epidemiologic, and economic circumstances PrEP is likely to be most cost-effective.
Methodology
We studied HIV transmission in New South Wales (NSW), Australia. New South Wales has approximately 350 annual HIV notifications with 80% of newly acquired HIV infections attributed to MSM [9, 10] . The HIV epidemic in NSW is thus similar to epidemics in other high-income settings, for example in the United States, the United Kingdom, and the Netherlands. The epidemic in NSW also broadly reflects the characteristics of HIV transmission in Australia generally. The Australian surveillance system does not report prevalence; however studies estimate that approximately 10% of MSM in NSW are infected with HIV [11] . Periodic surveys report high levels of HIV testing and treatment, with 60%-80% of men surveyed currently taking antiretroviral treatment [12] . Men who have sex with men in NSW are highly knowledgeable about HIV and practice a number of risk-reduction behaviors based on the disclosure of HIV serostatus to partners [12] . Further population and epidemiological details are provided in the Supplementary Data and in our previous studies [13] [14] [15] .
Model Summary
We used a stochastic agent-based model of HIV transmission and progression to assess the effectiveness and cost-effectiveness of PrEP for HIV prevention among MSM living in NSW, Australia. We projected estimates of incidence, prevalence, health outcomes, and healthcare costs according to various PrEP-based interventions over a 10-year time horizon. We assumed a health provider perspective and discounted costs and health outcomes at 3.0% annually.
The model tracks HIV transmission within 60 000 men and is informed by extensive epidemiological, behavioral, and clinical data. It simulates the formation of, sexual activity within, and breakup of regular, casual, and group partnerships in the population. The model updates variables describing infection and disease status of HIV, disease progression, treatment status, sexual activity level, partnership availability, and current sexual partners of each individual in daily time-steps. Within the model, the characteristics associated with the type of sexual encounter determine the probability of HIV transmission.
We used this model previously to investigate other HIV interventions such as vaccination and increases in HIV diagnostic testing [13] [14] [15] . These studies provide extensive technical details of the model, including model parameter values and the calibration of the model to the HIV epidemic in NSW. We modified the model to incorporate PrEP interventions, the development of drug-resistant HIV due to PrEP, and the use of antiretroviral therapy (ART) regimens incorporating PrEP drugs. These modifications do not change the calibration of the model or the associated parameter values for 1996-2010 or the status quo simulation for projections over 2011-2020 in our previous work [13] [14] [15] . Table 1 presents the key model parameters for PrEP and the development of drug resistance. We provide further technical details of the model as Supplementary Data (Section 1).
Modeling PrEP-Based Interventions
We investigated the impact of PrEP interventions by assigning a proportion of HIV-negative or undiagnosed MSM to be taking PrEP in a number of theoretical simulated scenarios. These scenarios were based on available trial data and plausible assumptions. The scenarios we investigated include prioritizing PrEP for 10%-30% of the general MSM population, 15%-30% of MSM with >10-50 sexual partners per 6 months, and 15%-30% of HIV-negative MSM in discordant regular partnerships. Although Australia is a high-income country and could potentially afford PrEP for the entire HIV-negative MSM population, we assumed a maximum coverage of 30% based on studies of willingness to use PrEP and informal PrEP use among MSM [34, 35] .
Overall, the iPrEX trial observed a 44% reduction in the probability of acquiring HIV (73% among fully adherent participants and >90% for those with detectable drug) [1] . Among individuals in the model who are adherent and therefore have detectable drug, we assumed a PrEP efficacy of 95% against wild-type virus and 40% against PrEP-drug resistant virus (based on the iPrEX trial results for those with detectable drug and the efficacy overall [1] ). We assumed PrEP provided no protection for those with poor adherence and therefore undetectable drug. The base case analysis assumes that 75% of MSM taking PrEP have detectable drug in each scenario, representing a 75% probability of adherence among MSM taking PrEP. We carried out sensitivity analyses varying the probability of adherence between 40% and 90%.
To date, PrEP studies have not identified any significant safety concerns associated with daily use of FTC-TDF and so we have not considered toxicity and drug-related adverse events in our model [1, 2, 36] . Behavioral disinhibition is an additional concern with PrEP; however, there is no conclusive evidence that PrEP causes an increase in high-risk sexual behavior [1, 36, 37] . Therefore, we assumed no change in increased partners or unsafe sex in our base case analyses. However, we investigated its impact in sensitivity analysis by simulating scenarios with 25%-75% reductions in condom use in partnerships where 1 partner is taking PrEP.
Cost and Utility Assumptions
We estimated the annual operating cost of providing PrEP interventions to MSM living in Australia using a health provider perspective. For uninfected individuals receiving PrEP in the model, patient monitoring costs were based on the current Centers for Disease Control and Prevention recommendations [38] . These include HIV antibody testing and screening for sexually transmitted infections every 2-3 months and monitoring serum creatinine levels every 3 months. We based the cost of PrEP on the most recently published dispensed price for maximum quantity (DPMQ) of tenofovir with emtricitabine on the Pharmaceutical Benefits Scheme website [39] -with costs associated with receiving PrEP adjusted according to an individual's adherence level in the model. The model also includes the cost of HIV-related medical care and treatment after infection. Published DPMQs on the PBS website [40] informed the cost of ART (we did not consider special pricing arrangements). The S100 Highly Specialized Drugs private cost figures were used for all ART costs in the base case analysis. It is acknowledged that prescribing behavior varies substantially and therefore sensitivity analysis is conducted on all ART cost estimates. We estimated first, second, third, and subsequent lines of ART to cost $10 685, $19 364, $31 411, and $28 162, per patient per year, respectively. In addition, the Medicare Benefits Schedule [41] and National Hospital Cost Data Collection cost weights [42] were used to estimate the cost of routine medical and laboratory testing and hospitalization costs. We estimated healthcare use from the literature and therapeutic guidelines. For the complete detail on all cost inputs, please refer to the Supplementary Data, Section 2.
There are several studies reporting quality of life estimates for people living with HIV and AIDS. The work of Tengs and Lin is commonly cited for utility estimates [28] . The authors conducted a meta-analysis and report pooled utility estimates of 0.70 for patients with AIDS, 0.82 for patients with symptomatic HIV, and 0.94 for asymptomatic HIV patients. In our base case analysis, the health states "CD4 + ≥500 cells/μL" and "CD4 + 350-499 cells/μL" were mapped to the utility for asymptomatic infection, "CD4 + 200-349 cells/μL" to symptomatic infection, and "CD4 + <200 cells/μL" to AIDS. Due to the large variations in estimates of utility scores, we also performed a sensitivity analysis of quality of life estimates from a variety of literature sources [29] [30] [31] [32] .
RESULTS

Preexposure Prophylaxis for the General MSM Population
In the absence of PrEP, we estimate 2388 new infections to occur among MSM in NSW during the next 10 years ( Table 2) . As illustrated in Figure 1 , the results from our analysis demonstrate the use of PrEP to have potential for reducing the incidence of HIV in the general MSM population (Figure 1 ). PrEP in 30% of the MSM population reduced the number of new infections to 1670, accounting for a 30.1% reduction in incidence, and accumulated 2142 additional QALYs. Although PrEP has potential for averting a considerable proportion of new infections among the MSM population, it is expensive. As the percentage of MSM taking PrEP increased, the costs associated with medical treatment and care rose. The use of PrEP in 10%-30% of the entire NSW MSM population was projected to cost an additional $316-$952 million over the next 10 years, resulting in ICERs of >$400 000 per QALYG compared with the status quo.
Preexposure Prophylaxis for Groups at Higher Risk of Infection
Targeting MSM at higher risk of infection improved the cost-effectiveness of PrEP (Figure 2 ). We found that targeting MSM with sexual partnerships ranging between >10 to >50 partners within 6 months reduced the cost considerably compared to targeting the entire MSM population. The incremental cost of these strategies ranged between approximately $31 and $331 million. However, these strategies were also associated with lower effectiveness. The QALYG ranged between 228 and 1503 and averted between 82 and 535 infections over the course of 10 years. Consequently, the ICERs for these strategies remained >$110 000 per QALYG-above what is considered to be cost-effective for Australian settings.
We found that targeting HIV-negative men in a discordant regular partnership was the most cost-effective of all the strategies analyzed (Figure 2 ). The incremental cost of providing PrEP to 15%-30% of HIV-negative men in discordant partnerships ranged between approximately $4.4 million and $12.3 million over 10 years. The infections averted and QALYG from 30% coverage of men in discordant partnerships is similar to that gained when targeting 10%-20% of the MSM population ( Table 2) . As a result, these strategies have extremely costeffective ICERs, ranging between $8399 and $11 575, for 15% and 30%, respectively, of HIV-negative men in discordant regular partnerships taking PrEP.
Sensitivity Analysis
In sensitivity analysis, we found the cost of PrEP had a large influence on the cost-effectiveness of PrEP (Supplementary Data, Section 3). For the Australian setting, we estimate the cost of TDF/FTC-based PrEP to be $9597 per person-year. With this cost, we projected the use of PrEP in 10%-30% of the entire NSW MSM population (adherence 75%) would cost an additional $316-$952 million over the next 10 years and resulted in ICERs of >$400 000 per QALYG compared with the status quo. If the cost of TDF/FTC-based PrEP falls to prices similar to those of commonly used first-line antiretroviral therapies (approximately $3000 per person-year), the budget impact dropped to $112-$338 million over the next 10 years and resulted in ICERs ranging between $157 911 and 185 851 per QALYG for coverage of 30% and 10%, respectively. Furthermore, at this lowered PrEP price, targeting 15% of MSM in discordant regular partnerships became a cost-saving strategy.
Other than the expense associated with PrEP, adherence and behavioral disinhibition are the primary concerns with the introduction of PrEP [43, 44] . In 1-way sensitivity analysis, a reduction of condom use of 75% in partnerships where 1 partner is taking PrEP increased the ICER of the most cost-effective strategy (15% coverage in discordant regular partnerships) from $8399 to $18 382. Reducing adherence from 75% to 40% reduced the ICER from $8399 to $7078.
DISCUSSION
This study suggests that PrEP could reduce the incidence of HIV among MSM living in Australia. Preexposure prophylaxis targeted for 30% of the MSM population reduced the number of new infections from 2388 to 1670, accounting for a 30.1% reduction in incidence over 10 years. However, based on the current treatment and monitoring cost of TDF-FTC-based PrEP and HIV-related medical care and treatment after infection, we estimated that PrEP for 10%-30% of the entire NSW MSM population to cost >$400 000 per QALYG. Therefore, from the Australian costeffectiveness perspective, providing PrEP to the general MSM population is not cost-effective. Targeting a smaller group of MSM at higher risk of infection improves the cost-effectiveness of PrEP. The most cost-effective strategies targeted HIV-negative men in a discordant regular partnership; ICERs ranged between $8399 and $11 575 per QALYG for coverage ranging between 15% and 30%, respectively. The findings in this study are dependent on several unknown assumptions. At present, real-world data on changed safe-sex behaviors and adherence among people taking PrEP is lacking. These data are critical for accurately assessing the cost-effectiveness of PrEP. Our base case analysis assumed 75% adherence, and no change to safe sex practices. Whether or not this reflects reality remains unknown. Condom use reductions did not have a substantial impact on the model. A reduction of condom use of 75% in partnerships where 1 partner is taking PrEP increased the ICER of the most cost-effective strategy (15% coverage in discordant regular partnerships) from $8399 to $18 382. Although proportionally this is a considerable increase, the ICER remains cost-effective. This is primarily due to the high level of PrEP effectiveness assumed in men with detectable drug levels and the high level of adherence to PrEP in our model population. For example, if we had 75% adherence, but 100% reduction in condom use, there would be little change in new infections as we assumed PrEP has 95% efficacy against wild-type virus. However, it is important to note that whereas our model appears to be insensitive to a reduction in condom use, the model does not take into account a reduction in condom use among the wider MSM population not taking PrEP or the cost and utility associated with the transmission of other sexually transmitted infections. In addition, poor adherence in combination with a reduction of condom use would have a significant impact on incidence. Therefore, we emphasize that ongoing risk-reduction counseling during visits to healthcare professions during PrEP monitoring remains important.
Previous cost-effectiveness studies and the current study demonstrate that PrEP is most cost-effective when targeting MSM at high risk of infection and PrEP is least cost-effective when targeting the general MSM population. Our study suggests it is not cost-effective to target MSM based solely on the number of sexual partnerships they have. We found that targeting MSM with sexual partnerships ranging between >10 and >50 partners within 6 months reduced the overall cost compared to targeting the entire MSM population but still generated ICERs >$110 000 per QALYG. We suggest reaching higher-risk MSM through targeting of HIV-negative men in a discordant regular partnership.
Our modeling analysis has limitations. Although there is a large amount of data describing the sexual behavior of MSM in NSW, translating these data into appropriate parameter values is difficult, particularly for those describing group sex, serosorting, strategic positioning, and sexual behavior within regular partnerships. However, we were able to represent these behaviors while also accurately reflecting the trends in HIV epidemiology up to 2010. We do not capture variations in PrEP use over time. Men with undetectable drug levels may increase their adherence at times of higher risk and receive some protection from PrEP, making it more cost-effective. Figure 2 . The incremental cost-effectiveness plane. 1, 10% men who have sex with men (MSM); 2, 20% MSM; 3, 30% MSM; 4, 15% MSM with >10 partners per 6 months; 5, 15% MSM with >20 partners per 6 months; 6, 15% MSM with >50 partners per 6 months; 7, 30% MSM with >10 partners per 6 months; 8, 30% MSM with >20 partners per 6 months; 9, 30% MSM with >50 partners per 6 months; 10, 15% HIV-negative men in discordant regular partnerships; 11, 30% HIVnegative men in discordant regular partnerships. Abbreviations: AUD, Australian dollar; ICER, incremental cost-effectiveness ratio; QALYG, quality-adjusted life-year gained. Parameters describing the development of drug resistance are also highly uncertain, particularly the efficacy of PrEP against majority-resistant viral strains. We saw only minimal levels of resistance develop. However, due to the reduced viral fitness and the high testing rate in the model population, our results will be robust to variations in the level of drug resistance in the population. Data describing the exact proportion of MSM on each ART regimen are difficult to obtain, and demarcating regimen lines or class stages is complex. This could affect our overall annual cost estimates for ART provision due to the variation in cost of different regimens. However, we used a simple model based on the only data available in Australia, and it provides a reasonable estimate for the number of MSM taking each line of ART. Changes to the proportion of MSM on each line have a similar effect on the cost of each scenario. Therefore, our rankings of PrEP interventions in terms of cost-effectiveness and our overall conclusions are maintained.
In conclusion, our modeled analysis demonstrates that PrEP provided to the wider MSM population would not be costeffective. Use among HIV-negative men in a discordant regular partnership would provide substantial health gain at a lower cost. We hope the findings from this study will provide insight to Australian policymakers and healthcare professionals as to whom to provide PrEP.
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